Neurocrine Biosciences Announces New Offering

Health and Healthcare

Published: February 18, 2015 8:50 am

Last Updated: February 18, 2015 8:51 am

Neurocrine Biosciences Inc. (NASDAQ: NBIX) has announced that it will have another public offering of its common stock. The total offering is expected to raise an aggregate of roughly $225 million.

J.P. Morgan and Deutsche Bank are acting as joint book-running managers for this offering.

The company expects that the net proceeds from the offering will be used to fund its research and development efforts, to prepare for commercialization efforts and for general corporate purposes, including working capital.

Neurocrine Biosciences develops innovative pharmaceuticals, in diseases with unmet medical needs, through its R&D platform, which is focused on neurological and endocrine based diseases and disorders. The company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc. (NYSE: ABBV), and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine Biosciences intends to maintain certain commercial rights to its vesicular monoamine transporter 2 inhibitor and grow into a fully integrated pharmaceutical company

Shares of Neurocrine Biosciences closed Tuesday up 0.3% up at $37.34. In premarket trading Wednesday, shares were relatively flat. The stock has a consensus analyst price target of $41.00 and a 52-week trading range of $12.17 to $38.58.

ALSO READ: 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.